Schein OD, Hochberg MC, Muñoz B, Tielsch JM, Bandeen-Roche K, Provost T, Anhalt GJ, West S. Dry Eye and Dry Mouth in the ElderlyA Population-Based Assessment. Arch Intern Med. 1999;159(12):1359-1363. doi:10.1001/archinte.159.12.1359
Symptoms of dry eye and dry mouth are common in the elderly and are often debilitating. Previous research on small populations has been inconsistent regarding the contribution to sicca symptoms of autoimmune markers, medication use, and other factors. The objective of this study was to determine the population prevalence of symptoms of dry eye and dry mouth and to evaluate possible risk factors.
This is a population-based study of 2481 individuals, aged 65 to 84 years, residing in Salisbury, Md, and identified by the Health Care Financing Medicare database. The main outcome measures included information on sicca symptoms, medical history, medication use, and joint examination results collected in a standardized manner. Autoimmune status was assessed in 1200 individuals by measuring antinuclear antibody, rheumatoid factor, and autoantibodies to the soluble nuclear antigens Ro/SS-A and La/SS-B by double immunodiffusion.
Approximately 27% of the population reported dry eye or dry mouth symptoms to be present often or all the time and 4.4% reported both. The prevalence of dry mouth (but not dry eye) symptoms increased with age, female sex, and white race. No association of sicca symptoms was found with rheumatoid arthritis, smoking, alcohol consumption, reproductive hormonal status, or the presence of autoantibodies. A strong, dose-response relationship was observed between sicca symptoms and the use of certain medication classes. The proportion of the population prevalence of sicca symptoms attributable to the use of drying medications was estimated at 62% for dry eye and dry mouth and 38% for dry eye or dry mouth symptoms.
Sicca symptoms are common in the elderly, and medication side effects appear to be a major underlying factor. Our results do not indicate an association between autoimmune status and sicca symptoms and do not support immunologic testing in persons with sicca symptoms in the absence of other important systemic features.
SYMPTOMS OF dry eye and dry mouth are common in the elderly and are frequently debilitating. When an individual presents with sicca symptoms, particularly if accompanied by musculoskeletal or other systemic complaints, considerations relating to the diagnosis of Sjogren syndrome arise, and an evaluation for evidence of an autoimmune process may ensue. In the United States, research on the epidemiology of sicca symptoms has largely been limited to selected populations such as outpatient clinics or nursing homes1- 5 where a variety of selection biases are likely to play a significant role in both estimates of the prevalence of symptoms as well as their relationship to systemic disease or other factors. We have previously reported the relationship between tests (Schirmer and Rose Bengal) and symptoms of dry eye and the prevalence of dry eye by varying definitions.6- 8 In summary, no significant association was seen between report of dry eye symptoms and either Rose Bengal or Schirmer testing nor was there any meaningful association between the results of Rose Bengal and Schirmer tests. Overall, 14.6% of the population reported symptoms of dry eye to be present often or all the time, and 3.5% were symptomatic and had either Rose Bengal scores or Schirmer test results in the lowest decile. Symptoms of dry mouth were found in 17% of the population and were closely associated with a measure of salivary production, the Saxon test.9,10
From a practical, clinical perspective, physicians are frequently presented with patient symptoms of dry eye, dry mouth, or vaginal dryness, particularly among the elderly. These symptoms are usually interpreted in the absence of physiologic tests of tear or salivary production. We report herein the population distribution of symptoms of dry eye and dry mouth and their association with putative risk factors.
The overall methodology for the Salisbury Eye Evaluation (SEE) Project has been previously described.11 Salisbury is located 106 miles from Baltimore on Maryland's eastern shore. The metropolitan area has a total population of 41,430, of whom 7004 are aged 65 years and older.12 Fifteen percent of the elderly population are African American.
The SEE Project contains 4 research projects whose overall purpose is to study visual function in the elderly from a common population-based perspective. The goal of the population recruitment was to enroll a random sample of 2500 men and women aged 65 to 84 years from Salisbury to have a home interview and a clinical examination at the SEE Project headquarters. The study size was chosen based on estimates of the prevalence of visual disability, and the actual sample was selected from the Health Care Financing Administration Medicare database. Eligibility criteria stipulated the following: (1) age between 65 and 84 years as of July 1, 1993; (2) residence in the Salisbury metropolitan area and alive at the time of contact; (3) noninstitutionalized status, ability to communicate in English and travel to the clinic for the assessments (housebound or extremely ill subjects were considered ineligible); and (4) a score of 18 or higher on the Mini-Mental State Examination.13
Recruitment was based on initial contact by letter and a subsequent visit from a study interviewer. After the home interview, an appointment at the SEE facility was made where the participant completed a series of vision and functional status tests, questionnaires, and clinical assessments that included the dry eye and dry mouth evaluation described below. The representativeness of the cohort examined has been reported in detail elsewhere.11,14
A dry eye symptom questionnaire6 consisting of questions relating to 6 symptoms was administered in a standardized fashion by a trained technician. Symptoms of dry mouth were assessed by asking each participant the questions "Does your mouth feel dry?" and "Do you wake up at night feeling your mouth is so dry that you need to drink fluids?" Each time a respondent indicated the presence of a dry eye or dry mouth symptom, he or she was asked to indicate whether the symptom was experienced rarely, sometimes, often, or all the time.
A total of 2199 (87.3%) of participants consented to blood drawing and the serum specimens from a sample of 1200 subjects were selected for immunologic testing. The sample was chosen to provide a population that included adequate representation from various subgroups selected on the basis of symptoms and test results. Specifically, the sample included (1) all subjects with at least 1 dry eye symptom or dry mouth symptom reported present often or all the time (n=350); (2) a random sample of 65% of subjects with a Rose Bengal score of 5 or more, or a Schirmer result of 5 mm or less (n=250); (3) a random sample of 38% of the subjects with no symptoms or signs of dry eye or dry mouth (n=600). Antinuclear antibodies were detected by incubating dilutions of sera with commercially prepared Hep-2 cells (Zeus Wampole, Raritan, NJ) followed by incubation with a polyvalent fluorescein isothiocyanate antihuman immunoglobulin. A quenching buffer containing 1 part 0.3-mol/L triethylenediamine, 0.1-mol/L Tris-hydrochloride (pH 9.0), and 9 parts glycerol (all from Sigma-Aldrich Corporation, St Louis, Mo) was applied, and slides were read under a Zeiss fluorescent microscope. A positive antinuclear antibody at a titer of 1:320 or greater is considered abnormal. Autoantibodies to soluble nuclear antigens Ro/SS-A and La/SS-B were detected by Ouchterlony double immunodiffusion against extracts of bovine spleen and rabbit thymus, prepared as described by Clark et al,15 and compared with control sera with known specificities. Titers of IgM rheumatoid factor were determined using latex agglutination.
A standardized medical history and exposure (smoking, alcohol, etc) questionnaire was completed on each individual, and a trained physician examiner evaluated each subject for clinical evidence of rheumatoid arthritis. A medical comorbidity score from 0 to 15 was constructed for each participant based on the number of self-reported histories of the following 15 conditions: arthritis, hip fracture, back problems, myocardial infarction, angina, congestive heart failure, intermittent claudication, high blood pressure, diabetes, emphysema, asthma since age 50 years, stroke, Parkinson disease, cancer in the past 5 years, and vertigo. A complete list of currently used medications determined by self-report was recorded for each participant and entered into the database using either the Drug Products Information Coding system or the Iowa Nonprescription Drug Products Information Coding System. For analysis, all drugs were recorded according to the Iowa Drug Information System.16
Associations with potential risk factors for sicca symptoms are presented as crude and adjusted odds ratios. Adjustment for age, race, and sex was performed using logistic regression models with age as a continuous variable. Each medication class in the Iowa Drug Information System (eg, antihistamine) was examined to assess its association with sicca symptoms. To assess the correlation among medication classes, pairwise odds ratios were estimated. In the analysis, medication classes with all pairwise odds ratios less than 3 were considered to have low correlations (less likely to be taken simultaneously). Those medication classes that had only low correlation with other classes were tested in a univariate fashion for their associations with the presence of dry eye and/or dry mouth (symptoms reported often or all the time). Medications with pairwise odds ratios of 3 or higher were considered highly correlated (more likely to be taken simultaneously), and the associations with dry eye and/or dry mouth were tested jointly in a single model. Those medication classes that had an independent association with dry eye or dry mouth of P<.10 and were in current use by at least 2% of the population were retained for further analysis.
Table 1 illustrates the distribution of sicca symptoms. Approximately 27% of the population reported (present often or all the time) dry eye or dry mouth symptoms, and 4.4% reported both. Report of dry eye or dry mouth symptoms was associated with increasing age, female sex, and white race. However, these associations were driven largely by symptoms of dry mouth, since no such associations were seen for dry eye alone.
Table 2 summarizes the relationship between classes of medications and symptoms of dry eye and/or dry mouth. Only medications used by more than 2% of the population and associated with sicca symptoms at a level of P<.10 are listed. The accompanying odds ratios indicate the association of each class of medication with symptoms of dry eye and/or dry mouth, adjusted for other classes of medication that were commonly used in conjunction by subjects.
Table 3 presents the association of potential risk factors with symptoms of dry eye and/or dry mouth. Each of the associations is presented in crude form and adjusted for age, sex, and race. No association of sicca symptoms was found for rheumatoid arthritis, smoking, alcohol, or the presence of autoantibodies (either individually or in combination). A strong association in a dose-response fashion was observed with both the number of reported comorbid medical conditions and use of certain medication classes. We explored the possibility that sicca symptoms are mediated through medication use rather than underlying medical comorbidities by computing the association (adjusted for age, sex, and race) of each medical comorbidity with dry eye and/or dry mouth. We reasoned that if the underlying comorbidities themselves were important risk factors on a population basis, that they should fall in order in a way that might reflect some biologic plausibility; however, they did not. For example, the medical conditions most closely associated with sicca symptoms were congestive heart failure and Parkinson disease. Arthritis ranked ninth of the 15 comorbidities assessed, and, as previously mentioned, a history of rheumatoid arthritis was also not associated with sicca symptoms. The proportion of the population prevalence of sicca symptoms attributable17 to the use of drying medications was estimated at 58% for dry eye and dry mouth symptoms and 37% for dry eye or dry mouth symptoms. Vaginal dryness was reported by 8.8% of the population and was associated with symptoms of dry eye and dry mouth (odds ratio, 3.7; 95% confidence interval, 2.1-6.4). No association was seen between vaginal dryness and medication use except for those using 6 or more of the "drying" medication classes.
Potential risk factors for sicca symptoms relevant only to the female population were examined separately. No association (or protective effect) was found for oophorectomy, current estrogen use, age of menarche or menopause, or total reproductive years with reported symptoms of dry eye or dry mouth.
In the Salisbury elderly population, 27.4% reported experiencing dry eye or dry mouth symptoms often or all the time and 4.4% experienced both. An extrapolation to the US population for those aged 65 to 84 years18 yields an estimate of more than 8 million with symptoms of dry eye or dry mouth and 1.3 million with both.
Our population-based sample does not support a significant association of autoimmunity (as assessed by rheumatoid factor, antinuclear antibody, and precipitins) with sicca symptoms. Of course, this does not mean that such an association does not exist for individuals with definite Sjögren syndrome or other connective tissue disease.19 However, in the general elderly population, sicca symptoms are unlikely to have an autoimmune basis, and our data do not provide a rationale for routine immunologic evaluation of elderly subjects who complain of sicca symptoms. Furthermore, the lack of association persisted after restricting the sicca group to those with both symptoms and test (Schirmer, Rose Bengal, Saxon10) results in the lowest deciles (data not shown).
In the Salisbury population, a significant association between the current use of certain medications and sicca symptoms was observed. The strong dose-response relationship and biologic plausibility of this relationship suggest a causal association. The mechanisms by which medications may cause symptoms of dry eye and dry mouth are multifactorial (eg, direct effect on gland function or dehydration). It is possible that some of the medication classes listed in Table 2 may have only an indirect or confounded association with symptoms. However, we have attempted to minimize this possibility by using statistical techniques to separate out those medication classes with independent effects.
The proportion of the population prevalence of sicca symptoms potentially attributable to drying medications was estimated at 62%, supporting the notion that medication side effect is a significant factor underlying sicca symptoms among the elderly. We also found a significant association of sicca symptoms and the number of comorbid medical conditions. It is likely that this association is mediated through the use of drugs rather than the comorbid conditions themselves since medical conditions known to cause dry eye and dry mouth were rare in this population and, when present (eg, rheumatoid arthritis), were not found to be independently associated with sicca symptoms.
From a practical or public health perspective, however, one cannot choose one's comorbidities, but there may be an opportunity to reduce or alter medication therapy. The results of this epidemiological investigation suggest that elderly patients should be queried about sicca symptoms and their medications be reviewed. If the sicca symptoms are present and bothersome, consideration may be given to altering the medical regimen.
Accepted for publication October 14, 1998.
This work was supported by grant P01-A10184 from the National Institutes of Health, Bethesda, Md, and performed at the Johns Hopkins University School of Medicine, Baltimore, Md.
Reprints: Oliver D. Schein, MD, 116 Wilmer Bldg, Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21287-9019 (e-mail: email@example.com).